TY - JOUR
T1 - Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI
AU - Vos, M.
AU - Starmans, M. P.A.
AU - Timbergen, M. J.M.
AU - van der Voort, S. R.
AU - Padmos, G. A.
AU - Kessels, W.
AU - Niessen, W. J.
AU - van Leenders, G. J.L.H.
AU - Grünhagen, D. J.
AU - Sleijfer, S.
AU - Verhoef, C.
AU - Klein, S.
AU - Visser, J. J.
N1 - Funding Information: M.V. and M.P.A.S. contributed equally to this study. The authors thank E. H. G. Oei and D. F. Hanff for classifying the lipomatous tumours. This study was financed by the Stichting Coolsingel (reference no. 567), a Dutch non‐profit foundation. M.P.A.S. acknowledges funding from the research programme STRaTeGy (project no. 14929‐14930), which is partly financed by the Netherlands Organization for Scientific Research (NWO). W.J.N. is founder, scientific lead and stock holder of Quantib. Disclosure : The authors declare no other conflicts of interest. Funding Information: M.V. and M.P.A.S. contributed equally to this study. The authors thank E. H. G. Oei and D. F. Hanff for classifying the lipomatous tumours. This study was financed by the Stichting Coolsingel (reference no. 567), a Dutch non-profit foundation. M.P.A.S. acknowledges funding from the research programme STRaTeGy (project no. 14929-14930), which is partly financed by the Netherlands Organization for Scientific Research (NWO). W.J.N. is founder, scientific lead and stock holder of Quantib. Disclosure: The authors declare no other conflicts of interest. Publisher Copyright: © 2019 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from lipoma. Currently, this distinction is made by testing for MDM2 amplification, which requires a biopsy. The aim of this study was to develop a noninvasive method to predict MDM2 amplification status using radiomics features derived from MRI. Methods: Patients with an MDM2-negative lipoma or MDM2-positive WDLPS and a pretreatment T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 2018 were included. When available, other MRI sequences were included in the radiomics analysis. Features describing intensity, shape and texture were extracted from the tumour region. Classification was performed using various machine learning approaches. Evaluation was performed through a 100 times random-split cross-validation. The performance of the models was compared with the performance of three expert radiologists. Results: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and originated from 41 different MRI scanners, resulting in wide heterogeneity in imaging hardware and acquisition protocols. The radiomics model based on T1 imaging features alone resulted in a mean area under the curve (AUC) of 0·83, sensitivity of 0·68 and specificity of 0·84. Adding the T2-weighted imaging features in an explorative analysis improved the model to a mean AUC of 0·89, sensitivity of 0·74 and specificity of 0·88. The three radiologists scored an AUC of 0·74 and 0·72 and 0·61 respectively; a sensitivity of 0·74, 0·91 and 0·64; and a specificity of 0·55, 0·36 and 0·59. Conclusion: Radiomics is a promising, non-invasive method for differentiating between WDLPS and lipoma, outperforming the scores of the radiologists. Further optimization and validation is needed before introduction into clinical practice.
AB - Background: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from lipoma. Currently, this distinction is made by testing for MDM2 amplification, which requires a biopsy. The aim of this study was to develop a noninvasive method to predict MDM2 amplification status using radiomics features derived from MRI. Methods: Patients with an MDM2-negative lipoma or MDM2-positive WDLPS and a pretreatment T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 2018 were included. When available, other MRI sequences were included in the radiomics analysis. Features describing intensity, shape and texture were extracted from the tumour region. Classification was performed using various machine learning approaches. Evaluation was performed through a 100 times random-split cross-validation. The performance of the models was compared with the performance of three expert radiologists. Results: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and originated from 41 different MRI scanners, resulting in wide heterogeneity in imaging hardware and acquisition protocols. The radiomics model based on T1 imaging features alone resulted in a mean area under the curve (AUC) of 0·83, sensitivity of 0·68 and specificity of 0·84. Adding the T2-weighted imaging features in an explorative analysis improved the model to a mean AUC of 0·89, sensitivity of 0·74 and specificity of 0·88. The three radiologists scored an AUC of 0·74 and 0·72 and 0·61 respectively; a sensitivity of 0·74, 0·91 and 0·64; and a specificity of 0·55, 0·36 and 0·59. Conclusion: Radiomics is a promising, non-invasive method for differentiating between WDLPS and lipoma, outperforming the scores of the radiologists. Further optimization and validation is needed before introduction into clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85075246027&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/bjs.11410
DO - https://doi.org/10.1002/bjs.11410
M3 - Article
C2 - 31747074
SN - 0007-1323
VL - 106
SP - 1800
EP - 1809
JO - British Journal of Surgery
JF - British Journal of Surgery
IS - 13
ER -